On the stock market since 2016, it operates in the world of health and science. It has 6,200 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
Average growth of 22% a year over the last 4 years. Every year shown ended in profit.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades below its recent peak — about 15% off the top. A pullback, not a collapse.
The net profit margin is 18% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 20% a year on average.
There is $497.0M in the vault; even if every debt were paid off, $246.6M would remain.
The company’s market value is 33 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, MEDP sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: MEDP is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.